Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials

Mamadaly Boudhabhay¹, Thomas Barnetche² and Pascale Vergne-Salle³, ¹CHU de Limoges, Limoges, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU de Limoges, Limoges, France

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Janus kinase (JAK), PRO, quality of life and rheumatoid arthritis (RA)

Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Recent studies comparing JAK-inhibitors (Jak-i) and adalimumab seem to show a better efficacy of JAK-i on patient-reported outcomes in rheumatoid arthritis (RA). As there is no study comparing directly the JAK-i with other biologic DMARDs (bDMARDs), we performed a meta-analysis and compared the effect size of JAK-i and bDMARD versus synthetic DMARDs (sDMARDs) on quality of life

Methods:

We performed a systematic review of the literature until May 2018 using database including : MEDLINE (via PUBMED), EMBASE and abstracts from the ACR and EULAR congresses 2015-2017. We selected all randomized controlled trials (RCT) comparing quality of life (evaluated by SF36) in patient with rheumatoid arthritis treated with bDMARD or JAK-i versus sDMARDs. We performed meta-analysis comparing the effect size of JAK-i (versus sDMARDs) and bDMARD (versus sDMARDs) on PCS SF36 and MCS SF36 at 12 weeks

Statistical analysis determined in each study effect size.

Pooled ES were computed by meta-analysis. Data were analyzed using the inverse variance approach.

Results:

The literature search identified240 articles plus one found by manuel search and no congress abstract. Finally, 44 articles met the inclusion criteria.

JAK-i and bDMARD showed higher level of quality of life than sDMARDs. The results concerning the meta-analysis comparing the effect size are:

For the SF36 PCS at 12 weeks: JAK-i: +4,82 IC95% [3,88, 5.77] and bDMARDs : +3,99 IC95% [2,81, 5,18]
For the SF36 MCS a 12 weeks: JAK-i: +3,42 IC95% [2.24, 4,60] and bDMARD: 2,99 IC95% [2.02, 3.96]

The range of the confidence intervals seems similar between JAK-I and bDMARDs.

SF36 PCS at 12 weeks:

-Results for JAK-i:

Conclusion:

In this meta-analysis, JAK-inhibitor and bDMARD showed better SF36 PCS and MCS at 12 weeks in comparison with sDMARDs.

The range of the confidence intervals seems similar between JAK-I and bDMARDs, suggesting a similar efficiency on the components of the SF36.

More head-to-head studies are needed to draw definitive conclusions on potential efficacy differences between JAK-inhibitor and bDMARDs in RA.

Disclosure: M. Boudhabhay, None; T. Barnetche, Roche SAS, 5,Chugai Pharma France, 5; P. Vergne-Salle, None.

To cite this abstract in AMA style:

Boudhabhay M, Barnetche T, Vergne-Salle P. Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/effect-of-jak-inhibitor-versus-bdmards-on-quality-of-life-in-rheumatoid-arthritis-a-meta-analysis-of-randomized-controlled-trials/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-jak-inhibitor-versus-bdmards-on-quality-of-life-in-rheumatoid-arthritis-a-meta-analysis-of-randomized-controlled-trials/